{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:45:47Z","timestamp":1793115947531,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["792494"],"award-info":[{"award-number":["792494"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.06.079","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:08:08Z","timestamp":1594343288000},"page":"5572-5576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Ethics of a partially effective dengue vaccine: Lessons from the Philippines"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-348X","authenticated-orcid":false,"given":"Scott B.","family":"Halstead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah C.","family":"Katzelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Markoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-9944","authenticated-orcid":false,"given":"Maira","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonila R.","family":"Dans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio L.","family":"Dans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.079_b0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.06.079_b0010","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition","volume":"386","author":"Murray","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.079_b0015","unstructured":"WPRO. Dengue in Phiippines, 2019. 2019."},{"key":"10.1016\/j.vaccine.2020.06.079_b0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.239.4839.476","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.079_b0025","unstructured":"WHO. Annex 2. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Replacement of Annex 1 of WHO Technical Report Series, No. 932. WHO Technical Report Series, Annex 2, No 979, 2013. Geneva, Switzerland: World Health Organization; 2013."},{"key":"10.1016\/j.vaccine.2020.06.079_b0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2020.06.079_b0035","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.079_b0040","unstructured":"Secretariat. Background Paper on Dengue Vaccines, SAGE Working Group on Dengue Vaccine. Geneva: World Health Organization 2016."},{"key":"10.1016\/j.vaccine.2020.06.079_b0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol."},{"key":"10.1016\/j.vaccine.2020.06.079_b0050","unstructured":"WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016, conclusions and recommendations. Weekly Epidemiological Record. 2016;91:265-84."},{"key":"10.1016\/j.vaccine.2020.06.079_b0055","unstructured":"WHO. Global Advisory Committee on Vaccine Safety, 15-16 June 2016. Weekly Epidemiological Record. 2016;91:341-8."},{"key":"10.1016\/j.vaccine.2020.06.079_b0060","unstructured":"WHO. A Toolkit for national dengue burden estimation. Geneva: World Health Organization; 2018."},{"key":"10.1016\/j.vaccine.2020.06.079_b0065","unstructured":"WHO. Informing vaccination programs: a guide to the design and conduct of dengue serosurveys. . Geneva: World Health Organization; 2017."},{"key":"10.1016\/j.vaccine.2020.06.079_b0070","unstructured":"WHO. Dengue vaccine: WHO position paper \u2013 July 2016. Weekly Epidemiological Record. 2016;91:349-64."},{"key":"10.1016\/j.vaccine.2020.06.079_b0075","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2020.06.079_b0080","unstructured":"Dengvaxia El."},{"key":"10.1016\/j.vaccine.2020.06.079_b0085","unstructured":"Dengvaxia Fl."},{"key":"10.1016\/j.vaccine.2020.06.079_b0090","unstructured":"WHO. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. In: Department of Immunization VaB, editor. Geneva, Switzerland: World Health Organization; 2008. p. 441."},{"key":"10.1016\/j.vaccine.2020.06.079_b0095","unstructured":"WHO. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva: WHO; 2011. p. 88."},{"key":"10.1016\/j.vaccine.2020.06.079_b0100","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.079_b0105","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/hv.21224","article-title":"Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2\u201345 y: Phase II randomized controlled trial in Singapore","volume":"8","author":"Sin Leo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.079_b0110","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.079_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.06.079_b0120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garcia","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2020.06.079_b0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.079_b0130","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1016\/j.vaccine.2015.11.023","article-title":"Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.079_b0135","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1080\/21645515.2018.1445448","article-title":"Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine","volume":"14","author":"Halstead","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.079_b0140","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of Repeat Hospital Admissions for Dengue to Estimate the Frequency of Third or Fourth Dengue Infections Resulting in Admissions and Dengue Hemorrhagic Fever, and Serotype Sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.06.079_b0145","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(19)32525-5","article-title":"Vaccine-attributable severe dengue in the Philippines","volume":"394","author":"Wilder-Smith","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.079_b0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12688\/wellcomeopenres.15507.1","article-title":"Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines","volume":"4","author":"Flasche","year":"2019","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2020.06.079_b0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.365.6457.961","article-title":"Controversy over dengue vaccine risk","volume":"365","author":"Cohen","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.079_b0160","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1126\/science.aaz6159","article-title":"Misguided approach to dengue vaccine risk","volume":"366","author":"Wilder-Smith","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.079_b0165","first-page":"223","article-title":"Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection","volume":"81","author":"Guzman","year":"2002","journal-title":"PAHO J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.06.079_b0170","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1473-3099(18)30126-9","article-title":"The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy","volume":"18","author":"Anderson","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.079_b0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMp1804094","article-title":"Trolleyology and the Dengue Vaccine Dilemma","volume":"379","author":"Rosenbaum","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.079_b0180","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1016\/j.vaccine.2017.08.066","article-title":"Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness","volume":"35","author":"Wichmann","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.079_b0185","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.079_b0190","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2214-109X(18)30295-X","article-title":"Dengue vaccine: reliably determining previous exposure","volume":"6","author":"Arien","year":"2018","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.vaccine.2020.06.079_b0195","unstructured":"WHO. Dengue vaccine: WHO position paper - September 2018. Weekly Epidemiological Record. 2018;93:457-76."},{"key":"10.1016\/j.vaccine.2020.06.079_b0200","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/infdis\/jix678","article-title":"Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report","volume":"217","author":"Goncalves","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.079_b0205","first-page":"8506","article-title":"Informed Consent in Obligatory Vaccinations?","volume":"24","author":"Zagaja","year":"2018","journal-title":"Med Sci Monitor Int Med J Experiment Clin Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:48Z","timestamp":1759401888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20308823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20308823"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethics of a partially effective dengue vaccine: Lessons from the Philippines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}